Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptajem1625

PASSWORD:
* * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'REGISTRY' AT 11:21:25 ON 19 MAR 2009
FILE 'REGISTRY' ENTERED AT 11:21:25 ON 19 MAR 2009

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	217.17	221.21

=>
Uploading C:\Program Files\Stnexp\Queries\10-560,327 prelim search.str





chain nodes :
11 12 13 14 15 16 17
ring nodes :
1 2 3 4 5 6
chain bonds :
2-17 5-11 11-12 12-13 13-14 14-15 14-16
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :
1-2 1-6 2-3 2-17 3-4 4-5 5-6 5-11 11-12 14-15 14-16
exact bonds :
12-13 13-14
isolated ring systems :
containing 1 :

G1:Cb,Hy

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 11:CLASS 12:CLASS 13:CLASS
14:CLASS 15:CLASS 16:CLASS 17:CLASS

L3 STRUCTURE UPLOADED

=> d l3
L3 HAS NO ANSWERS
L3 STR



G1 Cb,Hy

Structure attributes must be viewed using STN Express query preparation.

=> s l3 sss sam
SAMPLE SEARCH INITIATED 11:21:59 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 40 TO ITERATE

100.0% PROCESSED 40 ITERATIONS 1 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 421 TO 1179
PROJECTED ANSWERS: 1 TO 80

L4 1 SEA SSS SAM L3

=> s l3 sss full
FULL SEARCH INITIATED 11:22:08 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 752 TO ITERATE

100.0% PROCESSED 752 ITERATIONS 30 ANSWERS

SEARCH TIME: 00.00.01

L5 30 SEA SSS FUL L3

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	403.53	407.57

FILE 'CAPLUS' ENTERED AT 11:22:24 ON 19 MAR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 19 Mar 2009 VOL 150 ISS 12
FILE LAST UPDATED: 18 Mar 2009 (20090318/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l5
L6 4 L5

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L6 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2006:542587 CAPLUS
DOCUMENT NUMBER: 145:46274
TITLE: Preparation of peptide sulfonamides as cysteine protease inhibitors
INVENTOR(S): Woo, Soon H.; Vivian, Randall W.; Link, John O.
PATENT ASSIGNEE(S): Axys Pharmaceuticals, Inc., USA
SOURCE: PCT Int. Appl., 99 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006060810	A1	20060608	WO 2005-US44093	20051201
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1819667	A1	20070822	EP 2005-853104	20051201
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008522976	T	20080703	JP 2007-544617	20051201

PRIORITY APPLN. INFO.:		
US 2004-632702P	P	20041202
WO 2005-US44093	W	20051201

OTHER SOURCE(S): CASREACT 145:46274; MARPAT 145:46274
GI



I

AB The invention relates to peptide nitriles R5CR5aR5bNHCH(X-SO2NR3R4)CONHCR1R2CN [R1, R2 are independently is H, alkyl, or haloalkyl; or CR1R2 is substituted cycloalkylene; X is alkylene;

L6 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
R3, R4 are independently H, alkyl, aryl, heteroaryl, aralkyl, heteroaralkyl, cycloalkyl, etc.; or NR3R4 is heterocyclyl or bridged azabicyclic ring; R5 is H, alkyl, haloalkyl, (un)substituted aryl, heteroaryl, or heterocycloalkyl; R5a is CHF2, CF3, CF2CF3, CCl3, CFCl2, CF2Cl, CCl2CF3, CF2CHF2, CF2CF2CF3, or CF2CF2CHF2; R5b is H or haloalkyl] or their pharmaceutically-acceptable salts which are inhibitors of cysteine proteases, in particular cathepsins B, K, L, F, and S, and are therefore useful for treating diseases mediated by these proteases. An example is peptide I, which was prepd. by a multistep sequence involving reactions of 2-(benzyloxycarbonylamino)-3-(chlorosulfonyl)propionic acid benzyl ester, morpholine, 2,2,2-trifluoro-1(R)-(4-fluorophenyl)ethanol (prepn. given), and 1-aminocyclopropanecarbonitrile hydrochloride.
IT 890040-16-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of peptide sulfonamides as cysteine protease inhibitors)
RN 890040-16-1 CAPLUS
CN Propanamide, N-(1-cyanocyclopropyl)-3-[[4-(4-pyridinyl)-1-piperidinyl]sulfonyl]-2-[[(1S)-2,2,2-trifluoro-1-(4-fluorophenyl)ethyl]amino]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2004:1154675 CAPLUS
DOCUMENT NUMBER: 142:93685
TITLE: Preparation of hydroxamate sulfonamides as CD23 shedding inhibitors
INVENTOR(S): Owen, David Alan; Watson, Robert John; Allen, Daniel Rees; Sharpe, Andrew; Dyke, Hazel Joan
PATENT ASSIGNEE(S): Celltech R & D Limited, UK
SOURCE: PCT Int. Appl., 55 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004113298	A1	20041229	WO 2004-GB2646	20040618
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004249499	A1	20041229	AU 2004-249499	20040618
CA 2528316	A1	20041229	CA 2004-2528316	20040618
EP 1648868	A1	20060426	EP 2004-742999	20040618
EP 1648868	B1	20061115		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006527755	T	20061207	JP 2006-516455	20040618
AT 345328	T	20061215	AT 2004-742999	20040618
ES 2273278	T3	20070501	ES 2004-742999	20040618
US 20060276507	A1	20061207	US 2006-560327	20060523

PRIORITY APPLN. INFO.:		
GB 2003-14246	A	20030619
GB 2003-25832	A	20031105
WO 2004-GB2646	W	20040618

OTHER SOURCE(S): MARPAT 142:93685
GI

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



I



II

AB Piperidine and related heterocyclic derivs. of formula I [X = (CH2)n; Y = (CH2)m; n, m = 1-3; R1 = alkyl, aryl, heteroaryl, (hetero)cycloalkyl, alkylaryl, etc.; R2 = H, alkyl; R3, R4 = H, alkyl; R1R2, R3R4 = cycloalkyl, heterocycloalkyl] are prepared as potent inhibitors of CD23 shedding which are useful in the treatment and/or prevention of allergic, inflammatory and neoplastic diseases. Thus, II was prepared from 4-(2-methyl-4-fluorophenyl)piperidine and 2-chlorosulfonylmethyl-3-methylbutyric acid tert-Bu ester (preparation given).
The prepared compds. had IC50 values < 1.0 μM in the plasma membrane CD23 shedding assay.
IT 815618-14-5P 815618-15-6P 815618-16-7P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of hydroxamate piperidine sulfonamides as CD23 shedding inhibitors)
RN 815618-14-5 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1R)-1-[[[4-(2,4-dichlorophenyl)-1-piperidinyl]sulfonyl]methyl]-2-(hydroxyamino)-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 815618-15-6 CAPLUS
CN 1-Piperidinecarboxylic acid, 4-[(1R)-1-[[[4-(2-chloro-4-fluorophenyl)-1-

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
piperidinyl]sulfonyl]methyl]-2-(hydroxyamino)-2-oxoethyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.



RN 815618-16-7 CAPLUS
CN 4-Piperidineacetamide, α-[[[4-(2-chloro-4-fluorophenyl)-1-piperidinyl]sulfonyl]methyl]-N-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



IT 815617-96-0P 815617-97-1P 815617-98-2P
815617-99-3P 815618-00-9P 815618-01-0P
815618-02-1P 815618-03-2P 815618-04-3P
815618-05-4P 815618-06-5P 815618-07-6P
815618-08-7P 815618-09-8P 815618-10-1P
815618-13-4P 815618-17-8P 815618-18-9P
815618-19-0P 815618-20-3P 815618-21-4P
815618-22-5P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxamate piperidine sulfonamides as CD23 shedding inhibitors)

RN 815617-96-0 CAPLUS
CN Butanamide, 2-[[[4-(2-ethoxyphenyl)-1-piperidinyl]sulfonyl]methyl]-N-hydroxy-3-methyl- (CA INDEX NAME)



RN 815617-97-1 CAPLUS
CN Butanamide, 2-[[[4-(2-chlorophenyl)-1-piperidinyl]sulfonyl]methyl]-N-hydroxy-3-methyl- (CA INDEX NAME)



RN 815617-98-2 CAPLUS
CN Butanamide, 2-[[[4-(4-chloro-2-methoxyphenyl)-1-piperidinyl]sulfonyl]methyl]-N-hydroxy-3-methyl- (CA INDEX NAME)



RN 815617-99-3 CAPLUS
CN Butanamide, 2-[[[4-(4-fluoro-2-methylphenyl)-1-piperidinyl]sulfonyl]methyl]-N-hydroxy-3-methyl- (CA INDEX NAME)

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 815618-00-9 CAPLUS
CN Butanamide, 2-[[[4-[2-(difluoromethoxy)phenyl]-1-piperidinyl]sulfonyl]methyl]-N-hydroxy-3-methyl- (CA INDEX NAME)



RN 815618-01-0 CAPLUS
CN Butanamide, 2-[[[4-(2-fluorophenyl)-1-piperidinyl]sulfonyl]methyl]-N-hydroxy-3-methyl- (CA INDEX NAME)



RN 815618-02-1 CAPLUS
CN Butanamide, N-hydroxy-3-methyl-2-[[[4-[2-(trifluoromethyl)phenyl]-1-piperidinyl]sulfonyl]methyl]- (CA INDEX NAME)

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 815618-03-2 CAPLUS
CN Benzenepropanamide, N-hydroxy-α-[[[4-[2-(trifluoromethyl)phenyl]-1-piperidinyl]sulfonyl]methyl]- (CA INDEX NAME)



RN 815618-04-3 CAPLUS
CN Benzenepropanamide, α-[[[4-(2-fluorophenyl)-1-piperidinyl]sulfonyl]methyl]-N-hydroxy- (CA INDEX NAME)



RN 815618-05-4 CAPLUS
CN Benzenepropanamide, N-hydroxy-α-[[[4-(2-methoxyphenyl)-1-piperidinyl]sulfonyl]methyl]- (CA INDEX NAME)



L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RN 815618-06-5 CAPLUS
CN Benzenepropanamide, N-hydroxy-α-[[[4-(2-methylphenyl)-1-piperidinyl]sulfonyl]methyl]- (CA INDEX NAME)



RN 815618-07-6 CAPLUS
CN Benzeneacetamide, N-hydroxy-α-[[[4-(2-methoxyphenyl)-1-piperidinyl]sulfonyl]methyl]- (CA INDEX NAME)



RN 815618-08-7 CAPLUS
CN Butanamide, N-hydroxy-2-[[[4-(2-methoxyphenyl)-1-piperidinyl]sulfonyl]methyl]-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 815618-09-8 CAPLUS
CN Butanamide, N-hydroxy-3-methyl-2-[[[4-(2-methylphenyl)-1-piperidinyl]sulfonyl]methyl]-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
CN 4-Piperidineacetamide, α-[[[4-(2-chloro-4-fluorophenyl)-1-piperidinyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 815618-18-9 CAPLUS
CN 4-Piperidineacetamide, α-[[[4-(2,4-dichlorophenyl)-1-piperidinyl]sulfonyl]methyl]-N-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 815618-19-0 CAPLUS
CN 2H-Pyran-4-acetamide, α-[[[4-(2-chloro-4-fluorophenyl)-1-piperidinyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 815618-10-1 CAPLUS
CN Butanamide, 2-[[[4-(2-fluorophenyl)-1-piperidinyl]sulfonyl]methyl]-N-hydroxy-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 815618-13-4 CAPLUS
CN Butanamide, 2-[[[4-(2,4-dichlorophenyl)-1-piperidinyl]sulfonyl]methyl]-N-hydroxy-3-methyl-, (2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 815618-17-8 CAPLUS

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



RN 815618-20-3 CAPLUS
CN Benzenepropanamide, α-[[[4-(2-chloro-4-fluorophenyl)-1-piperidinyl]sulfonyl]methyl]-3,4-difluoro-N-hydroxy-, (αR)- (CA INDEX NAME)

Absolute stereochemistry.



RN 815618-21-4 CAPLUS
CN Cyclopentaneacetamide, N-hydroxy-α-[[[4-(2-methylphenyl)-1-piperidinyl]sulfonyl]methyl]- (CA INDEX NAME)



RN 815618-22-5 CAPLUS
CN Butanamide, N-hydroxy-2-[[[4-(2-methoxyphenyl)-1-piperidinyl]sulfonyl]methyl]-3-methyl- (CA INDEX NAME)

L6 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2001:636067 CAPLUS
DOCUMENT NUMBER: 135:195577
TITLE: Preparation of arylpiperazines and arylpiperidines as metalloproteinase inhibiting agents
INVENTOR(S): Barlaam, Bernard Christophe; Dowell, Robert Ian; Newcombe, Nicholas John; Tucker, Howard; Waterson, David
PATENT ASSIGNEE(S): Astrazeneca AB, Swed.; Astrazeneca UK Limited
SOURCE: PCT Int. Appl., 35 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001062751	A1	20010830	WO 2001-GB616	20010215
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2396971	A1	20010830	CA 2001-2396971	20010215
EP 1261595	A1	20021204	EP 2001-905883	20010215
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001008500	A	20030429	BR 2001-8500	20010215
JP 2003524008	T	20030812	JP 2001-562533	20010215
ZA 2002005845	A	20031022	ZA 2002-5845	20020722
NO 2002003951	A	20020820	NO 2002-3951	20020820
MX 2002008112	A	20021129	MX 2002-8112	20020820
US 20030139419	A1	20030724	US 2002-204389	20020927
PRIORITY APPLN. INFO.:			EP 2000-400469 A	20000221
			WO 2001-GB616 W	20010215

OTHER SOURCE(S): MARPAT 135:195577
GI

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)



AB The title compds. [I; B = (un)substituted Ph, 2-pyridyl, 2-pyridyloxy, 4-pyrimidinyl; X = C, N; R1 = (trimethyl-1-hydantoin)alkyl, (un)substituted Ph, phenylalkyl, etc.], useful as metalloproteinase inhibitors, especially as inhibitors of MMP 13, were prepared E.g., a 5-step synthesis of I [B = 4-FC6H4; X = CH; R1 = CH2Ph] was given.

IT 357187-71-4P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of arylpiperazines and arylpiperidines as metalloproteinase inhibiting agents)
RN 357187-71-4 CAPLUS
CN Benzenepropanamide, α-[[[4-(4-fluorophenyl)-1-piperidinyl]sulfonyl]methyl]-N-hydroxy- (CA INDEX NAME)



IT 357187-82-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylpiperazines and arylpiperidines as metalloproteinase inhibiting agents)
RN 357187-82-7 CAPLUS
CN Benzenepropanamide, α-[[[4-(4-fluorophenyl)-1-piperidinyl]sulfonyl]methyl]-N-(phenylmethoxy)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS

L6 ANSWER 3 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN
ACCESSION NUMBER: 2000:161257 CAPLUS
DOCUMENT NUMBER: 132:194294
TITLE: Preparation of hydroxamic acid derivatives as proteinase inhibitors
INVENTOR(S): Martin, Fionna Mitchell
PATENT ASSIGNEE(S): British Biotech Pharmaceuticals Limited, UK
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000012477	A1	20000309	WO 1999-GB2826	19990827
W: AU, BR, CA, CN, CZ, GB, HU, IL, JP, KR, MX, NO, NZ, PL, RU, SG, SK, TR, US, ZA				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9956349	A	20000321	AU 1999-56349	19990827
EP 1107953	A1	20010620	EP 1999-943064	19990827
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2002523492	T	20020730	JP 2000-567510	19990827
US 6479502	B1	20021112	US 2001-763424	20010221
US 20030050310	A1	20030313	US 2002-242739	20020912

PRIORITY APPLN. INFO.: GB 1998-18830 A 19980829
GB 1998-28525 A 19981223
WO 1999-GB2826 W 19990827
US 2001-763424 A3 20010221

OTHER SOURCE(S): MARPAT 132:194294
GI

L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)


II III


IV

AB The title compds. WSO2CHR1CHR2X [I; X = CO2H, CONHOH; R2 = R3(ALK)m(Q)p(ALK)n (wherein R3 = H, (un)substituted cycloalkyl, cycloalkenyl, etc.; ALK = (un)substituted divalent alkylene; Q = O, S, SO, etc.; m, n, p = 0-1); R1 = R2, except that R1 is not H; W = II, III (wherein Y = O, S, SO, etc., and R4-R7 = R2, and R4a, R7a = H, alkyl; R4, R4a and R5 taken together with the carbon atoms to which they are attached form (un)substituted benzene or pyridine ring fused to cyclic amine ring, and R7a = H, alkyl, and R6 and R7 = R2; etc.)], useful in treating diseases resulting from over production of, or over responsiveness to, MMPs (no data), were prepared E.g., a multi-step synthesis of the title compound IV was given.

IT 260046-68-2P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of hydroxamic acid derivs. as proteinase inhibitors)

RN 260046-68-2 CAPLUS
CN Benzenebutanamide, β-[[4-(4-fluorophenyl)-1-piperidinyl]sulfonyl]-N-hydroxy- (CA INDEX NAME)



L6 ANSWER 4 OF 4 CAPLUS COPYRIGHT 2009 ACS on STN (Continued)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>